These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 22118194)
1. Elevated levels of interleukin-27 in patients with Sjögren's syndrome. Xia L; Shen H; Zhao L; Lu J Scand J Rheumatol; 2012 Feb; 41(1):73-4. PubMed ID: 22118194 [No Abstract] [Full Text] [Related]
2. Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome. Zhao L; Yao L; Yuan L; Xia L; Shen H; Lu J Cytokine; 2013 Oct; 64(1):22-4. PubMed ID: 23910012 [TBL] [Abstract][Full Text] [Related]
3. Expression of interleukin-22 in Sjögren's syndrome: significant correlation with disease parameters. Lavoie TN; Stewart CM; Berg KM; Li Y; Nguyen CQ Scand J Immunol; 2011 Oct; 74(4):377-82. PubMed ID: 21645026 [TBL] [Abstract][Full Text] [Related]
4. [Serum IL-21 level in patients with primary Sjogren's syndrome and clinical significance of IL-21]. Yuan SL; Jiang L; Zhang XL; Li SF; Duan HM; Wang XF Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Feb; 23(2):124-6. PubMed ID: 17286904 [TBL] [Abstract][Full Text] [Related]
5. Decrease in the ratio of polyreactive IgG titers with IgG concentration is associated with long-term complications of primary Sjögren's syndrome. Argyropoulou OD; Gunti S; Kapsogeorgou EK; Notkins AL; Tzioufas AG Clin Exp Rheumatol; 2018; 36 Suppl 112(3):239-240. PubMed ID: 30156547 [No Abstract] [Full Text] [Related]
6. Elevated IL-37, IL-18 and IL-18BP serum concentrations in patients with primary Sjögren's syndrome. Liuqing W; Liping X; Hui S; Jing L J Investig Med; 2017 Mar; 65(3):717-721. PubMed ID: 28057714 [TBL] [Abstract][Full Text] [Related]
7. Circulating soluble CD30 levels in primary Sjögren's syndrome, SLE and rheumatoid arthritis. Ichikawa Y; Yoshida M; Yamada C; Horiki T; Hoshina Y; Uchiyama M Clin Exp Rheumatol; 1998; 16(6):759-60. PubMed ID: 9844777 [No Abstract] [Full Text] [Related]
8. Sjögren's syndrome: hyperviscosity and intermediate complexes. Blaylock WM; Waller M; Normansell DE Ann Intern Med; 1974 Jan; 80(1):27-34. PubMed ID: 4129658 [No Abstract] [Full Text] [Related]
10. Decreased CD4+CD25+bright T cells in peripheral blood of patients with primary Sjogren's syndrome. Liu MF; Lin LH; Weng CT; Weng MY Lupus; 2008 Jan; 17(1):34-9. PubMed ID: 18089681 [TBL] [Abstract][Full Text] [Related]
11. Implications of immunomodulatory interleukins for the hyperimmunoglobulinemia of Sjögren's syndrome. Girón-González JA; Baturone R; Soto MJ; Márquez M; Macías I; Montes de Oca M; Medina F; Chozas N; García-Pérez S Cell Immunol; 2009; 259(1):56-60. PubMed ID: 19540455 [TBL] [Abstract][Full Text] [Related]
12. Serum level of IL-6 in patients with primary and secondary Sjögren's syndrome. Slezák R; Krejsek J; Kopecký O; Jelenová H Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(2):59-60. PubMed ID: 8584859 [TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptors in serum from patients with primary Sjögren's syndrome. Diamant M; Tvede N; Prause JU; Oxholm P Scand J Rheumatol; 1991; 20(5):370-2. PubMed ID: 1947901 [No Abstract] [Full Text] [Related]